Cite
HARVARD Citation
Gray, H. et al. (2016). Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for immunotherapy of cancer. 4 (1), pp. 1-10. [Online].